KENILWORTH, N.J.--(BUSINESS WIRE)--Dec 19, 2018--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the ...
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EuWBoR
Τετάρτη 19 Δεκεμβρίου 2018
FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer - Argus Press
FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer Argus Press
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EuWBoR
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EuWBoR
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.